Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.

Brahe, Cecilie Heegaard; Ørnbjerg, Lykke Midtbøll; Jacobsson, Lennart; Nissen, Michael J; Kristianslund, Eirik Klami; Mann, Herman; Santos, Maria José; Reino, Juan Gómez; Nordström, Dan; Rotar, Ziga; Gudbjornsson, Bjorn; Onen, Fatos; Codreanu, Catalin; Lindström, Ulf; Möller, Burkhard; Kvien, Tore K; Pavelka, Karel; Barcelos, Anabela; Sánchez-Piedra, Carlos; Eklund, Kari K; ... (2020). Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA. Rheumatology, 59(7), pp. 1640-1650. Oxford University Press 10.1093/rheumatology/kez427

[img] Text
kez427.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (618kB) | Request a copy

OBJECTIVE To investigate TNF inhibitor (TNFi) retention and response rates in European biologic-naïve patients with PsA. METHODS Prospectively collected data on PsA patients in routine care from 12 European registries were pooled. Heterogeneity in baseline characteristics between registries were explored (analysis of variance and pairwise comparison). Retention rates (Kaplan-Meier), clinical remission [28-joint count DAS (DAS28) <2.6; 28 joint Disease Activity index for Psoriatic Arthritis ⩽4] and ACR criteria for 20% improvement (ACR20)/ACR50/ACR70 were calculated, including LUNDEX adjustment. RESULTS Overall, 14 261 patients with PsA initiated a first TNFi. Considerable heterogeneity of baseline characteristics between registries was observed. The median 12-month retention rate (95% CI) was 77% (76, 78%), ranging from 68 to 90% across registries. Overall, DAS28/28 joint Disease Activity index for Psoriatic Arthritis remission rates at 6 months were 56%/27% (LUNDEX: 45%/22%). Six-month ACR20/50/70 responses were 53%/38%/22%, respectively. In patients initiating a first TNFi after 2009 with registered fulfilment of ClASsification for Psoriatic ARthritis (CASPAR) criteria (n = 1980) or registered one or more swollen joint at baseline (n = 5803), the retention rates and response rates were similar to those found overall. CONCLUSION Approximately half of >14 000 patients with PsA who initiated first TNFi treatment in routine care were in DAS28 remission after 6 months, and three-quarters were still on the drug after 1 year. Considerable heterogeneity in baseline characteristics and outcomes across registries was observed. The feasibility of creating a large European database of PsA patients treated in routine care was demonstrated, offering unique opportunities for research with real-world data.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology

UniBE Contributor:

Möller, Burkhard

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1462-0324

Publisher:

Oxford University Press

Language:

English

Submitter:

Burkhard Möller

Date Deposited:

08 Nov 2019 08:14

Last Modified:

25 Jun 2020 01:30

Publisher DOI:

10.1093/rheumatology/kez427

PubMed ID:

31665497

Uncontrolled Keywords:

DAPSA28 DAS28 TNFi drug survival effectiveness epidemiology psoriatic arthritis register response spondyloarthritis

BORIS DOI:

10.7892/boris.134768

URI:

https://boris.unibe.ch/id/eprint/134768

Actions (login required)

Edit item Edit item
Provide Feedback